Skip to content
Study details
Enrolling now

CAR T Cell Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

St. Jude Children's Research Hospital
NCT IDNCT06847269ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

25

Study length

about 5.9 years

Ages

≤21

Locations

1 site in TN

What this study is about

This trial is testing a new treatment called CAR T cell therapy for people with leukemia that has returned or not responded to other treatments. The treatment involves modifying immune cells to fight cancer cells. Researchers are looking at different doses of chemotherapy drugs, how the body processes these drugs, and how long the CAR T cells last in the body.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive CD19-CAR T cell Infusion
  • 2.Take Cyclophosphamide
  • 3.Take Fludarabine
  • +1 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

cell therapy, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, mesna

Drug routes

infusion, oral (Oral Tablet)

Endpoints

Primary: Fludarabine Pharmacokinetics

Body systems

Oncology